Skip to main content

Table 2 Incidence rates and risk of ischemic stroke associated with use of low-dose aspirin among patients with diabetes

From: Evaluation of low-dose aspirin for primary prevention of ischemic stroke among patients with diabetes: a retrospective cohort study

  

Aspirin non-user

Low-dose aspirin user

 
  

Event (N)

Person-years

Crude incidence rate (/1,000 person-years)

Event (N)

Person-years

Crude incidence rate (/1,000person-years)

Crude hazard ratio (95%CI)

Adjusted hazard ratio * (95% CI)

Whole matched cohort

158

48,725

3.2

340

44,592

5.4

1.64 (1.32-1.98)

1.73 (1.41-2.12)

Gender

Male

81

27,565

2.9

137

25,224

5.4

1.86 (1.56-2.23)

1.93 (1.46-2.55)

 

Female

77

21,160

3.6

103

19,368

5.3

1.45 (1.08-1.95)

1.52 (1.13-2.15)

Age

40-69

85

39,758

2.1

136

37,060

3.7

1.69 (1.28-2.22)

1.81 (1.37-2.38)

 

70-99

73

8,967

8.1

104

7,867

11.6

1.65 (1.23-2.23)

1.72 (1.27-2.33)

Type of diabetes

Type 1 only

14

3,078

4.5

19

2,287

8.3

1.74 (0.87-3.47)

1.82 (0.90-3.68)

 

Type 2 and others

144

45,647

3.2

221

42,305

5.2

1.61 (1.31-1.99)

1.73 (1.40-2.14)

Diabetes with essential hypertension

Yes

97

24,791

3.9

135

21,306

6.3

1.59 (1.23-2.07)

1.69 (1.30-2.20)

No

61

23,934

2.5

105

23,286

4.5

1.70 (1.24-2.33)

1.81 (1.32-2.51)

Diabetes with dyslipidemia

Yes

39

13,501

2.9

48

11,255

4.3

1.44 (0.94-2.14)

1.68 (1.09-2.57)

No

119

35,224

3.4

192

33,337

5.8

1.65 (1.31-2.08)

1.75 (1.39-2.21)

  1. CI: confidence interval.
  2. *Adjusted Hazard Ratio calculated using Cox proportional hazard model adjusting for insurance type, anti-diabetic medications at baseline, use of statins, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta blockers, calcium channel blockers and thiazide diuretics during follow-up.